Precision BioSciences (DTIL) Stock Analysis & Winston Score
Precision BioSciences is a small biotech company that uses a gene-editing tool it invented, called ARCUS, to change or fix DNA inside living cells. Its main focus is on making cancer treatments — specifically a type of therapy where edited immune cells are used to attack tumors — as well as working on treatments for genetic diseases. The company sells research licenses to other biotech and pharmaceutical companies that want to use its ARCUS technology. Precision BioSciences earns money through licensing deals, research collaborations, and milestone payments from partners, which explains its high gross margin despite losing money overall. It operates primarily in the United States and is a very small company with a market cap around $100 million. The ARCUS gene-editing platform is its core competitive asset, but the company faces significant risk from cash burn and competition from larger gene-editing players like CRISPR Therapeutics and Beam Therapeutics, making its path to profitability uncertain.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Good (10/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)

